期刊
CANCER RESEARCH
卷 82, 期 8, 页码 1548-1559出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-21-2556
关键词
-
类别
资金
- Wellcome Trust [207793/Z/17/Z]
- AMMF [2016/108, 2017/115]
- Cancer Research UK [C52499/A27948]
- MRC university grant
- Wellcome Trust [207793/Z/17/Z] Funding Source: Wellcome Trust
This study investigated the role of genetic heterogeneity in driving intrahepatic cholangiocarcinoma (ICC) and identified novel tumor suppressors that interact with the RAS oncoprotein to promote ICC growth.
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy of the bile ducts within the liver characterized by high levels of genetic heterogeneity. In the context of such genetic variability, determining which oncogenic mutations drive ICC growth has been difficult, and developing modes of patient stratification and targeted therapies remains challenging. Here we model the interactions between rare mutations with more common driver genes and combine in silico analysis of patient data with highly multiplexed in vivo CRISPR-spCas9 screens to perform a functional in vivo study into the role genetic heterogeneity plays in driving ICC. Novel tumor suppressors were uncovered, which, when lost, cooperate with the RAS oncoprotein to drive ICC growth. Focusing on a set of driver mutations
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据